{
    "nct_id": "NCT06855771",
    "official_title": "A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies",
    "inclusion_criteria": "* Histologically confirmed diagnosis of NSCLC and homozygous MTAP deletion detected in tumor tissue and willingness to provide archival/fresh samples at screening for central MTAP status confirmation.\n* Advanced or metastatic NSCLC not amenable to curative therapies after progression on prior therapies at the time of enrollment (based on the American Joint Committee on Cancer, Ninth Edition).\n* At least 1 measurable lesion as per RECIST v1.1.\n* Documented radiographic disease progression on or after the most recent line of treatment.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Participant must be â‰¥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place) at the time of signing the ICF.\n* Capability to swallow tablets intact (without chewing or crushing).\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastases or carcinomatous meningitis.\n* History of gastrointestinal disease or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.\n* Prior treatment with a PRMT5 or MAT2A inhibitor.\n* Known severe hypersensitivity to study treatment and/or any of its excipients.\n* Other protocol-defined inclusion/exclusion criteria apply.",
    "miscellaneous_criteria": ""
}